Press Releases

Initiator Pharma A/S, a clinical-stage biotech company, today announced good progress in patient enrollment in its Phase 2a clinical proof-of-concept study evaluating pudafensine in women suffering from the genital pain condition, vulvodynia.

Initiator Pharma A/S, ett bioteknikbolag i klinisk fas, meddelar idag goda framsteg i patientrekryteringen till bolagets kliniska fas 2a proof-of-concept-studie som utvärderar pudafensine hos kvinnor med det genitala smärttillståndet vulvodyni.

Initiator Pharma A/S, a clinical-stage biotech company, today announced that the company has decided to focus fully on its most promising drug candidate, pudafensine, which is being developed for both vulvodynia and organic erectile dysfunction (ED). As part of this prioritization, the company will discontinue further development of IP2018.

Initiator Pharma A/S, ett bioteknikbolag i klinisk fas, meddelar idag att bolaget beslutat att fokusera fullt ut på sin mest lovande läkemedelskandidat pudafensine, som utvecklas för både vulvodyni och organisk erektil dysfunktion (ED). Som en del av denna prioritering kommer bolaget att avbryta den fortsatta utvecklingen av IP2018.

Initiator Pharma A/S, a clinical-stage biotech company, today announces that its CEO, Claus Elsborg Olesen, will present the latest developments at the Redeye Healthcare Day 2026, Wednesday April 14, at 09:20.

Initiator Pharma A/S, ett bioteknikbolag i klinisk fas, meddelar idag att vd Claus Elsborg Olesen kommer att presentera på Redeye Healthcare Day 2026, onsdag 14 april kl 09:20.